Semaglutide 2.4 mg (Wegovy) , a GLP-1 receptor agonist, is recommended by NICE (TA875) for adults with a BMI of 35 kg/m or above and at least one weight-related comorbidity, when used as part of a specialist weight management service for a maximum of two years
doi: 10.1152/physrev.00026.2013
Research has shown that patellar tendon tears are a rare injury
A patient carrying the GLP1R rs6923761 variant may have a genetic predisposition toward enhanced GLP-1 receptor function, while GIPR rs1800437 variants may influence dual-agonist mechanism engagement
This type of blindness, often known as NAION, is also increased by the use of Ozempic and Rybelsus, other drugs containing semaglutide produced by pharmaceutical manufacturer Novo Nordisk
First, methionine acts as a methyl donor in methylation pathways critical for detoxifying the liver and processing fats